NSU HPD Catalog 2021-2022

202 College of Pharmacy well as current pharmacotherapeutic approaches. Similarities and differences between humans and animals related to specific disease states will be discussed. Pharmacotherapeutic approaches to be discussed include human-labeled medications that are used extra-label in animals, medications that have both human-labeled and veterinary-labeled formulations, and medications exclusively approved to treat medical conditions in animals. OTC product use in animals will also be presented to better prepare pharmacy students for those unexpected questions asked by pet owners. Other topics include specific regulations regarding medications in animals, compounding, preventatives, pet insurance, and alternative medicine approaches. (32-0-2) PHRE 5427—Introduction to Pharmacometrics: Modeling and Simulation (IPMS) IPMS will expose the student to cutting-edge tools and techniques used to answer complicated problems in drug development and utilization. IPMS leverages information and knowledge from core biomedical and pharmaceutical courses together with mathematical modeling and simulation and clinical data from patients or published literature. Students will be required to synthesize the data to create models and perform simulations to answer problems with drug therapy. The course also includes hands-on training using standardmodeling and simulation software. Prerequisite: P3 Standing (32-0-2) PHRE 5429—Antimicrobial Stewardship Antimicrobial stewardship aims to optimize clinical outcomes while minimizing unintended consequences of antimicrobial use, including development of drug toxicity, selection of pathogenic organisms, and emergence of antimicrobial resistance. Principles of antimicrobial stewardship and concepts related to the management of infectious pathogens are the emphasis of this course. Upon completion of this course, students will be prepared to practice as a pharmacist in the forthcoming post-antibiotic era. (32-0-2) PHRE 5431—Oncologic Treatments and Pharmacogenomics This hybrid course introduces the basic molecular concepts of cancer and pharmacogenomics in the context of cancer treatment. It presents the current methodologies used in cutting-edge oncology for the treatment of two of the most common types of cancer: breast and colon. The standard-ofcare combinatorial regimens will be presented, as well as the treatment scenarios that are applied to advanced-stage and recurrent disease. Drugs that have increased patient tolerance to these genotoxic regimens will also be discussed. Finally, the application of next-generation sequencing of tumor DNA or RNA to determine which of the more than 300 druggable mutations exist in these tumors will be discussed, primarily in the cancer-recurrence setting. Prognostic tests based on RNA expression from tumors will be covered. Discussion of the rationale for insurance coverage of pharmacogenomics will be covered as well. The impact of oncologic pharmacogenomics on future clinical trials will also be examined. (32-0-2) PHRE 5445—Leadership, Engagement, and Development (LEAD) This course provides an in-depth look at the behaviors and skills needed to be an effective leader. Students are exposed to a variety of leadership theories and styles within the context of student leadership development. Communication styles, teamwork, cultural competence, and conflict management are examined within the interpersonal context. Course materials and activities challenge students to connect theory to practice and enhance communication skills through the use of student presentations on topics related to collaborative and interprofessional experiences. (16-0-1) PHRE 5447—Regulatory Affairs This course provides an exposure to the important and critical area of drug regulatory matters. It describes the role of federal laws, regulations, and the structure and operation of the U.S. Food and Drug Administration. It also compares similar agencies in other countries. (32-0-2) PHRE 5505—Consulting Pharmacy in Long-Term Care This course focuses on the practice of consulting pharmacy practice in long-term care facilities. It provides an overview of geriatric consulting statutes that regulate the activity of the consultant pharmacist, the Health Care Financing Administration survey guidelines, and the types of facilities required to have a consultant pharmacist. Students will apply the Pharmacists’ Patient Care Process in addressing geriatric patient medication-related needs in this setting. Prerequisite: P3 Standing/PHRC 5935 (32-0-2) PHRE 5511—Survey of Complementary Therapies This course provides students with information about complementary therapies that are frequently seen, or could be recommended, for various disease states. Nutritional supplements, herbal remedies, homeopathic remedies, and others will be studied. The proper dosing, side effects, and drug and disease state interactions will also be considered in recommending these therapies. (32-0-2) PHRE 5513—Special Population Needs and the Role of the Pharmacist This course uses the framework of social determinants of health and the ecological model and provides a holistic perspective to vulnerable and special populations. Students have an opportunity to explore the needs of special populations from a pharmacist’s perspective, enabling students to self-assess their preconceived knowledge and gain a newperspective to practice pharmacy. Students acquire knowledge about factors that influence and intersect with vulnerable populations. Students are expected to design an intervention for a population of their interests, applying the knowledge and skills they have